| Clinical feature |
no. |
% |
| Patients |
200 |
|
| Healthy Controls |
25 |
|
| Gender |
| Males |
128 |
64.0% |
| Female |
72 |
36.0% |
| Age |
| Age >45 |
71 |
35.5% |
| Age <45 |
129 |
64.5% |
| BCR-ABL transcripts |
| a2b2 |
59 |
29.5% |
| a2b3 |
124 |
62.0% |
| a2b2/ a2b3 |
17 |
8.5% |
| Staging of the disease |
|
|
| Chronic phase-CML |
81 |
40.5% |
| Accelerated phase-CML |
54 |
27.0% |
| Blast crisis-CML |
65 |
32.5% |
| Molecular Response |
| Major molecular response(MMR) |
50 |
25.0% |
| No molecular response |
150 |
75.0% |
| Haematological responses |
| Major haematological response(MHR) |
30 |
15.0% |
| Minor haematological response(mHR) |
46 |
23.0% |
| No haematological response |
124 |
77.0% |
| Type of therapy |
| Imatinib treated |
200 |
100% |
| Dasatinib treated (Imatinib failure) |
10 |
5.0% |
| Thrombocytopenia |
| Thrombocytopenia |
100 |
50.0% |
| No Thrombocytopenia |
100 |
50.0% |
